Susan K. FINSTON, JD/MPP, President
Susan has experience in microbial R&D and biopharma management. In 2008 She founded Amrita Therapeutics with biotech pioneer Ananda Chakrabarty, PhD (z”l)). In May 2021 she joined Princeton Capital Advisors, transactions arm of Albright Stonebridge Group (now DGA), as Senior Advisor, and is President, Finston Consulting since 2005. Past experience: She led the successful multi-year India patent reform campaign at PhRMA and served in the U.S. Foreign Service. She is a member of the Illinois State Bar and U.S. Supreme Court Bar.
Pascal NEUVILLE, PhD, General Manager
Pascal is past Chairman of the Quest for Change incubator network, and a member of the SATT Connectus Alsace Investment Committee. From 2008 to 2023, he was founder and CEO of Domain Therapeutics. Past experience includes as CSO of Faust Pharmaceuticals SA, a CNS drug discovery and development company and past President and Board Member of Alsace BioValley’s Board of Directors, the life science competitiveness cluster of Alsace. Pascal has a PhD in molecular biology from University of Strasbourg, France.
Anna KOSTRZAK, PhD., Head of Translational Research and Pharmacology
Anna is a senior expert in translational research and pharmacology with 15+ years’ experience across biopharma and academic environments. She has led preclinical and early clinical R&D programs in a range of indications from discoveryt through IND/IMPD. Anna has held leadership roles at Evora Biosciences, Theravetys (Institute Pasteur) and Invites Cancer Immunotherapeutics, managing cross-functional teams & international CRO/CDMO collaborations. She brings strong expertise in R&D integration, regulatory strategy and scientific decision making at critical development stages.
Yara TASRINI,PhD., Post Doc Researcher
Yara is a double threat, with dual background in microbiology and virology and focus on host-pathogen interactions. She applies rigorous molecular and microscopy techniques with additional experience in in vivo research models. Yara is supporting AMC Bio development of peptide therapies targeting major RNA viral pathogens like Dengue Fever within Professor Edouard Tuaillon’s Virology Department in Montpellier France.
Emilie BUREL, PhD., Project Manager
Emilie is committed to advancing antiviral research to benefit millions of patients around the world. She has a background in Genetics and Physiology and experience in microbial R&D, biopharma management and on genomic analysis (bioinformatics) of viruses. Emilie has special interest in COVID, post-infectious syndromes (Long COVID), and patient engagement. Emilie is mission driven, with a vision for every patient – including Long COVID patients – to receive timely diagnosis and effective treatment for viral disease.
Edouard TUAILLON, MD, PhD
AMC Bio Science Advisor
Edouard is Associate Professor of Medicine, Medical Director of the Biological Resource Center of the Montpellier, and an expert in microbiology and immunology
with over 200 publications, EU grants & international research
experience.
Nissim DARVISH, MD/DSc
Independent Board Member
Nissim Darvish is Managing General Partner at Eliraz Ventures, with deep expertise in translational science, M&A, and IPOs. Past leadership roles include OrbiMed and Pitango. He sites on numerous Boards, co-chairs the annual BioMed life sciences conference, and serves as faculty at an international cardiovascular innovation forum. Nissim holds 100+ patents and has been published widely in scientific journals.
Christian POLICARD, PhD
AMC Bio Strategic Advisor, Independent Board Member
Christian has traversed global biomed/biopharma scientific and business leadership. He has been Executive Vice-President and Executive Board Member of Sanofi, Director at Institut Pasteur, Founding Partner of Biotech Development Consulting and Chairman of Cellectis.
Current roles: Chairman of Theradiag and Panntherapi, Director and Treasurer of ATF/Technion, Senior Partner of Global Close Alliances, Senior Advisor of Vivalto Partners, and sits on numerous boards.
Susan F. Wilson, JD/MA
AMC Bio Board Member
Susan launched WilsonIPR consulting following 30+ years experience in the private sector and the US Federal government, with roles as Intel’s global IPR Director, and service in Departments of Commerce, State and Justice, the U.S. Customs Service, the U.S. Trade Representative’s Office (Executive Office of the President), and most recently as a Senior Level attorney at the U.S. Patent and Trademark Office.
Andrew Kochanowski, JD
AMC Bio Board Member
Andrew Kochanowski brings decades of experience in international negotiation, dispute resolution, US federal litigation, patent portfolio enforcement and international arbitration to AMC Bio. Last year Andrew became of counsel to his law firm and among other matters, joined AMC Bio’s board to advise the company on legal and other matters. He has been an early-stage investor to other companies as an adjunct to his professional legal career.
